If you or someone you care for takes prednisone or another corticosteroid for more than a few months, there is a drug class that should be part of the conversation with your doctor: bisphosphonates. These bone-protecting medications — including alendronate, risedronate, and zoledronic acid — are FDA-approved specifically for glucocorticoid-induced osteoporosis, the most common form of secondary osteoporosis and a condition that leads to fractures in 30 to 50 percent of patients on chronic steroid therapy. For families managing dementia, where corticosteroids may be prescribed for inflammatory conditions, autoimmune disorders, or chronic lung disease alongside cognitive decline, a preventable hip fracture can be the event that transforms a manageable caregiving situation into a crisis. The stakes are not abstract.
Consider a 72-year-old woman with moderate Alzheimer’s disease who has been taking 10 mg of prednisone daily for polymyalgia rheumatica. Within the first year of steroid use, she could lose 6 to 12 percent of her lumbar spine bone mineral density. If no one orders a bone density scan or starts a protective medication, she faces a five-fold higher risk of vertebral fracture compared to someone not taking steroids. A compression fracture means pain, immobility, hospitalization — and for a person with dementia, hospitalization often accelerates cognitive decline in ways that never fully reverse. This article walks through the science behind steroid-induced bone loss, the drugs that can prevent it, current guidelines from the American College of Rheumatology, a recent FDA labeling update from February 2026 that every patient and caregiver should know about, and the practical steps you can take to protect bones while managing conditions that require long-term steroids.
Table of Contents
- How Fast Do Steroids Destroy Bone, and Why Does It Matter for Dementia Patients?
- Which Bone-Protecting Drugs Work Best — and When They Fall Short
- What the 2022 ACR Guidelines Say Every Steroid Patient Should Get
- Comparing Your Options — Oral Pills, Infusions, and Injections
- The February 2026 FDA Warning That Changes the Risk Calculation
- Drug Holidays — Who Qualifies and Who Should Never Stop
- The Future of Bone Protection for Steroid Patients
- Conclusion
- Frequently Asked Questions
How Fast Do Steroids Destroy Bone, and Why Does It Matter for Dementia Patients?
The speed of bone loss from corticosteroids catches many patients and caregivers off guard. Fracture risk begins climbing within three to six months of starting steroid therapy and remains elevated for as long as the medication continues. Even doses as low as prednisone 2.5 mg daily — a level many physicians consider minimal — cause more than 8 percent trabecular bone mineral density loss after just 20 weeks. At higher doses of 7.5 mg per day or more, patients face a five-fold increase in vertebral fracture risk, a 2.2-fold increase in hip fracture risk, and a 1.6-fold increase in non-vertebral fractures compared to people not taking steroids. For people living with dementia, this is not simply an orthopedic concern. A hip fracture in an older adult with cognitive impairment carries roughly double the mortality risk compared to a cognitively intact person.
The post-surgical confusion, the anesthesia exposure, the weeks of limited mobility, the disruption of routine — all of these compound cognitive decline. Studies have consistently shown that hospitalization for any reason accelerates the trajectory of dementia, and fractures are among the most common preventable causes of hospitalization in older adults on steroids. The prevalence of steroid prescriptions makes this a widespread problem. According to Wallace and colleagues, writing in Clinical and Translational Science in 2023, 6.8 percent of Americans were prescribed oral corticosteroids annually between 2009 and 2018, with the rate rising from 6.4 to 7.7 percent over that period. One in five non-elderly adults with private insurance filled a short-term corticosteroid prescription within a three-year window. Many of these short courses become long courses when the underlying condition flares, and bone protection often lags behind or never starts at all.
Which Bone-Protecting Drugs Work Best — and When They Fall Short
Bisphosphonates remain the most commonly prescribed first-line treatment for glucocorticoid-induced osteoporosis. Alendronate (Fosamax), risedronate (Actonel), and zoledronic acid (Reclast) work by inhibiting osteoclasts, the cells responsible for breaking down bone tissue. They are relatively inexpensive, widely available, and backed by decades of clinical data. For many patients on long-term steroids, a weekly oral bisphosphonate tablet or an annual intravenous infusion of zoledronic acid is enough to meaningfully reduce fracture risk. However, bisphosphonates are not always the best choice, and they are not without drawbacks. A November 2025 network meta-analysis published in The Lancet Diabetes and Endocrinology found that denosumab (Prolia) and teriparatide (Forteo) reduce vertebral fracture risk more effectively than oral bisphosphonates in patients with glucocorticoid-induced osteoporosis. Denosumab and zoledronate also produced greater gains in bone mineral density than risedronate.
For patients with severe bone loss or those who have already fractured while on a bisphosphonate, these alternatives may be more appropriate. Newer bone-anabolic agents — abaloparatide and romosozumab — are now available for postmenopausal women with severe osteoporosis and high fracture risk, expanding the range of individualized treatment options. The limitation that matters most for dementia caregivers is adherence. Oral bisphosphonates must be taken on an empty stomach, with a full glass of water, while sitting upright for at least 30 minutes afterward to prevent esophageal irritation. For a person with moderate to advanced dementia who may not reliably follow these instructions, an oral bisphosphonate can be impractical or even dangerous. In these cases, an annual zoledronic acid infusion or twice-yearly denosumab injection — administered by a healthcare provider — may be far more realistic. The choice of drug should account not just for efficacy data but for the patient’s cognitive ability to use it safely.
What the 2022 ACR Guidelines Say Every Steroid Patient Should Get
The American College of Rheumatology published updated guidelines in October 2023 in Arthritis and Rheumatology that provide the clearest framework to date for preventing steroid-induced bone loss. The guideline strongly recommends pharmacologic treatment for all adults at moderate, high, or very high fracture risk who are taking 2.5 mg or more of prednisone daily for longer than three months. this is not a suggestion to consider treatment. It is a strong recommendation based on the best available evidence. The guidelines also call for an initial bone health assessment as soon as possible after starting steroids. This includes a clinical fracture history, a FRAX score for patients aged 40 and older, and bone mineral density testing via DEXA scan with vertebral fracture assessment or spinal X-ray.
In practice, this assessment is frequently delayed or skipped entirely — particularly when the prescribing physician is focused on the condition the steroid is treating and bone health falls through the cracks. For dementia patients, who often see multiple specialists with limited care coordination, this gap is even more pronounced. A caregiver who understands that bone assessment should happen at the start of steroid therapy — not months or years later — can advocate for this directly. For patients with severe glucocorticoid-induced osteoporosis, the 2025 Lancet review recommends sequential therapy: begin with a bone-anabolic agent such as teriparatide to actively build new bone, then transition to an antiresorptive drug like a bisphosphonate or denosumab to maintain the gains. This approach reflects a growing understanding that simply slowing bone breakdown may not be enough for patients who have already lost substantial bone density. It also underscores the importance of ongoing monitoring rather than a set-it-and-forget-it approach.
Comparing Your Options — Oral Pills, Infusions, and Injections
Choosing a bone-protecting drug involves trade-offs that matter differently depending on the patient’s situation. Oral bisphosphonates like alendronate and risedronate are the least expensive option and can be taken at home, but they require the upright-stomach protocol that makes them difficult for patients with swallowing problems, cognitive impairment, or gastrointestinal conditions. Generic alendronate costs as little as a few dollars per month, making it accessible even for patients with limited insurance coverage. Zoledronic acid, given as a once-yearly intravenous infusion, eliminates the daily or weekly adherence challenge entirely. A single appointment per year is far easier to manage for a caregiver coordinating dementia care. The trade-off is that it requires a clinic visit, the infusion takes at least 15 minutes, and some patients experience flu-like symptoms for a day or two afterward. Denosumab is a subcutaneous injection given every six months, also administered in a clinical setting, and it produces strong bone density gains.
But denosumab carries a critical caveat: if the drug is stopped, patients can experience rapid rebound bone loss and a surge in fracture risk. The Lancet 2025 review specifically notes that follow-up with a bisphosphonate is required after discontinuing denosumab to prevent this rebound effect. For a dementia patient whose care may become fragmented — a change in caregivers, a move to a memory care facility, a hospitalization that disrupts the injection schedule — this rebound risk is a serious practical concern. Teriparatide, a daily self-injection that stimulates new bone formation, is the most potent option for patients with severe bone loss but also the most demanding. It requires daily subcutaneous injections for up to two years, must be refrigerated, and is significantly more expensive than bisphosphonates. For a caregiver already managing complex medication regimens for dementia, adding a daily injection with cold-chain storage requirements may not be feasible. The conversation with the prescribing physician should weigh efficacy against the realities of the caregiving situation.
The February 2026 FDA Warning That Changes the Risk Calculation
On February 3, 2026, the FDA updated the labels for Fosamax and other bisphosphonates with a warning that should not be ignored. The revised labeling states that atypical fractures — unusual breaks that occur with minimal trauma — can happen in bones beyond the femur and may be bilateral, meaning the same bone on both sides of the body can fracture. This is an expansion of a previously known but narrowly defined risk. More directly relevant to steroid patients, the updated label specifically notes that concurrent glucocorticoid use may increase the risk of these atypical fractures from bisphosphonates. This creates a difficult clinical paradox: the very patients who most need bisphosphonates to prevent steroid-induced osteoporotic fractures may also face a heightened risk of an unusual fracture type caused by the bisphosphonate itself.
The absolute risk of atypical fractures remains low — far lower than the risk of osteoporotic fractures in an unprotected steroid patient — but it changes the monitoring conversation. Patients and caregivers should know to report new, dull, aching pain in the thigh, hip, groin, or other weight-bearing bones to their provider promptly, as this can be an early warning sign. This warning does not mean steroid patients should avoid bisphosphonates. The benefit-to-risk ratio still strongly favors treatment for most patients on chronic corticosteroids. But it does mean that the duration of bisphosphonate therapy and the possibility of drug holidays deserve more careful discussion, particularly for patients who have been on both steroids and bisphosphonates for years.
Drug Holidays — Who Qualifies and Who Should Never Stop
The concept of a bisphosphonate drug holiday has gained traction in recent years. Because bisphosphonates bind tightly to bone and continue working after the medication is stopped, some patients can take a break from treatment while retaining meaningful bone protection. The Mayo Clinic notes that reassessment is appropriate after five years of oral bisphosphonate use or three years of intravenous zoledronic acid. For patients with stable bone density and no recent fractures, a temporary pause may be reasonable.
However, this guidance applies primarily to patients with postmenopausal osteoporosis who are not taking glucocorticoids. Patients who remain on chronic steroids generally should not take a drug holiday, because the ongoing steroid exposure continues to actively destroy bone. Stopping the bisphosphonate while continuing the steroid removes the counterbalance and can lead to rapid bone loss. For dementia caregivers managing a loved one’s medication list, the temptation to simplify by dropping a medication that seems to be working — because nothing bad has happened — is understandable but potentially dangerous. The bisphosphonate is working precisely because it is preventing the fracture that would otherwise occur.
The Future of Bone Protection for Steroid Patients
The treatment landscape for glucocorticoid-induced osteoporosis is shifting. The availability of newer anabolic agents like romosozumab and abaloparatide, combined with growing evidence for sequential therapy strategies, means that physicians have more tools than ever to tailor treatment to individual risk profiles.
The 2025 Lancet review’s emphasis on starting with a bone-building drug before transitioning to a maintenance antiresorptive represents a more aggressive and potentially more effective approach than the traditional bisphosphonate-first strategy. For the dementia care community, the most important development may be less about which drug is prescribed and more about ensuring that bone protection is prescribed at all. Better integration of bone health screening into the care plans of steroid-dependent patients with cognitive impairment — through electronic health record alerts, caregiver education, and coordination between neurologists, rheumatologists, and primary care — could prevent thousands of fractures that currently derail dementia care trajectories every year.
Conclusion
Long-term corticosteroid use triggers bone loss that is both faster and more severe than most patients and caregivers realize. With fractures occurring in 30 to 50 percent of chronic steroid users and bone density declining measurably within weeks of starting therapy, protective treatment is not optional — it is essential. Bisphosphonates remain the most widely used first-line defense, but denosumab, teriparatide, and newer anabolic agents offer stronger options for patients with severe bone loss or practical barriers to oral medication. The 2022 ACR guidelines are unambiguous: anyone taking 2.5 mg or more of prednisone daily for more than three months who is at moderate or higher fracture risk should be on pharmacologic treatment. For families navigating dementia, the stakes of an unprotected skeleton on steroids are uniquely high.
A single hip fracture can permanently alter the course of cognitive decline, shift a person from home care to institutional care, and reduce life expectancy. If someone you care for is on long-term steroids and has not had a bone density assessment or a conversation about bone protection, that conversation needs to happen now — not at the next annual visit, not after the first fracture, but now. Bring it up with the prescribing physician. Ask about DEXA screening. Ask whether a bisphosphonate, denosumab, or another agent is appropriate. This is one of the most preventable catastrophes in dementia care, and prevention starts with a single question.
Frequently Asked Questions
How soon after starting steroids should bone protection begin?
The 2022 ACR guideline recommends assessment as soon as possible after starting glucocorticoids. Fracture risk begins rising within three to six months of starting steroid therapy, so bone density testing and treatment discussions should not be delayed. For patients already identified as moderate or high fracture risk, pharmacologic treatment should start alongside or shortly after beginning steroids.
Does my loved one with dementia need a bone density scan if they are on a low dose of prednisone?
Yes. Even low doses of 2.5 to 7.5 mg per day of prednisone increase hip and vertebral fracture risk compared to non-users. A DEXA scan with vertebral fracture assessment provides the baseline needed to make informed treatment decisions. Cognitive impairment does not change the bone biology — it only increases the consequences of a fracture.
Can bisphosphonates be crushed or given in liquid form for someone who has trouble swallowing pills?
Alendronate is available as an oral solution, which may be easier for some patients. However, the requirement to remain upright for 30 minutes after taking the medication still applies. For patients with significant swallowing or compliance difficulties, an annual zoledronic acid infusion or twice-yearly denosumab injection may be more practical and equally or more effective.
What happens if denosumab injections are missed or stopped?
Stopping denosumab without transitioning to another bone-protecting medication can cause rapid rebound bone loss and a significant increase in fracture risk. The 2025 Lancet review emphasizes that a bisphosphonate must follow denosumab discontinuation. If there is any risk that injections could be missed due to caregiving transitions or changes in medical providers, this should factor into the initial drug choice.
Are there side effects of bisphosphonates that dementia caregivers should watch for?
Common side effects of oral bisphosphonates include gastrointestinal discomfort and esophageal irritation. The February 2026 FDA label update warns that atypical fractures can occur in bones beyond the femur and may be bilateral, with concurrent glucocorticoid use potentially increasing this risk. Caregivers should report any new persistent pain in the thigh, hip, groin, or other bones to the patient’s physician.
Should steroids be stopped to protect bones?
That decision belongs to the physician managing the condition that requires steroids. In many cases, steroids cannot be safely stopped or reduced without disease flare. The goal of bone-protecting drugs is precisely to allow necessary steroid therapy to continue while minimizing skeletal damage. The lowest effective steroid dose should always be used, but bone protection should not depend on being able to reduce or eliminate the steroid.
